After a Difficult Summer, X4 Celebrates Phase III Victory in WHIM Syndrome (Update) | BioSpace
Paula Ragan, President and CEO of X4/Courtesy of the company Four months after implementing a restructuring initiative aimed at expanding cash flow, X4 Pharmaceuticals celebrates the first positive results, published on Tuesday, of its pivotal phase III trial of mavorixafor in WHIM syndrome. In July, the Boston-based biopharmaceutical company made the difficult decision to cut …